checkAd

    EQS-News  121  0 Kommentare Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease - Seite 3


    02.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com

    Lesen Sie auch

    1828587  02.02.2024 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1828587&application_name=news&site_id=wallstreet
    The Abivax Stock at the time of publication of the news with a raise of +2,51 % to 12,24EUR on Tradegate stock exchange (01. Februar 2024, 13:15 Uhr).

    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease - Seite 3 EQS-News: ABIVAX / Key word(s): Study Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease 02.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this …